Proud to share this recent work published in @JACCJournals. Thanks to @robmentz for the fantastic mentorship and to all my fabulous co-authors for their contributions!
🔴Effects of Sacubitril/Valsartan vs Valsartan in De Novo vs Acute on Chronic HFpEF and HFmrEF
👉 👥466 participants
���️33% novo HF
➡️67% chronic HF
🚫nonsignificant ↘️ in NT-proBNP with SV vs valsartan
🎯win ratio was nominally in favor of SV for both de novo & chronic HF
📁 https://t.co/A7hWFkxPwP @JACCJournals
I am so excited to have matched at Duke for Internal Medicine Residency training! Thankful for all the mentors, friends, and family who have helped me along the way. #MatchDay2022@IMResidencyDuke
Last year during Step 1 dedicated, I went to a cardiologist after progressive exertional back pain over a couple months and after a positive stress test was found to have a full proximal LAD occlusion - s/p DES, I started MS3 on time and yesterday I took Step 1. Never give up
In-Hospital Initiation of SGLT2i for HFrEF
https://t.co/paz2aCLzSx
We argue in @JACCJournals that starting SGLT2i in HFrEF once stabilized may
���️ risk of never initiating GDMT / initiating after substantial delay
⬆️ clinical benefits of CV risk within days to
weeks
Patients with diabetes and HF have worse physical function but show strong improvement with physical rehabilitation. Quality of life and frailty may be resistant to change. Thanks to @robmentz for being a great mentor! Full article: https://t.co/QLlucd0UqJ
Very excited to share my first lead-author publication presented at #HFSA2021 w/ simultaneous publication in the American Journal of Medicine. We looked at the effect of diabetes in physical function in patients hospitalized with HF in the REHAB-HF trial